ClinicalTrials.gg
CompletedNCT04508530Updated Jan 7, 2026Results posted

Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

A Phase 3 interventional study of Panzyga and Placebo in Pediatric Acute-Onset Neuropsychiatric Syndrome, sponsored by Octapharma. Completed at 12 sites in 3 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Octapharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Study summary

A Superiority Study To Compare The Effect of Panzyga Versus Placebo in Patients with Pediatric Acute-onset Neuropsychiatric Syndrome

02

Conditions studied

  • Pediatric Acute-Onset Neuropsychiatric Syndrome
03

In context

Lead sponsor

Octapharma is the lead sponsor of 71 studies on the registry; 8 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 16 (94%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥6 to ≤17 years of age.
  2. Confirmed diagnosis of moderate to severe PANS with prominent and stable obsessive-compulsive disorder (OCD) symptoms (i.e. Clinical Global Impression (CGI)-Severity-OCD rating of ≥ 4 or higher on 2 ratings without a change of more than 1 unit between measurements) based on the following criteria:

    1. Abrupt dramatic onset of OCD meeting diagnostic criteria for OCD as confirmed by the MINI-KID-7
    2. Concurrent presence of additional neuropsychiatric symptoms, with similarly severe and acute onset, from at least two of the following seven categories, that are not better explained by a known neurologic or medical disorder, such as Sydenham chorea (SC), systemic lupus erythematosus, Tourette disorder, or other:

      • Anxiety (particularly, separation anxiety)
      • Emotional lability (extreme mood swings) and/or depression
      • Irritability, aggression and/or severely oppositional behaviors
      • Behavioral (developmental) regression (examples, talking baby talk,throwing temper tantrums, etc.)
      • Deterioration in school performance
      • Sensory or motor abnormalities
      • Somatic signs and symptoms, including sleep disturbances, bed wetting or urinary frequency
  3. Signed of patient's legal representative(s)/guardians(s). If patients are old enough to understand the risks and benefits of the study (as determined by each institution), they should provide written assent/consent.
  4. Legal representative(s)/guardians(s) must be capable of understanding and complying with the relevant aspects of the study protocol.

Patients who will additionally meet the following optional inclusion criteria will be identified as patients with Pediatric neuropsychiatric disorders associated with streptococcal infection (PANDAS):

  1. An episodic (relapsing-remitting) course of symptom severity
  2. Temporal association between symptoms onset or exacerbation and infections with group A streptococcal infection (GAS, positive throat culture and/or anti-GAS antibody titers)

Exclusion criteria

Exclusion Criteria

  1. Onset of current PANS episode more than 12 months prior to first medicinal product (IMP) treatment.
  2. a. In patients with relapsing episodes: Onset of initial PANS episode more than 24 months prior to first IMP treatment.

    b. In patients with relapsing episodes: Absence of significant improvement and stabilization between the episodes according to investigator's judgment.

  3. to receiving intravenous immunoglobulin (IVIG), including:

    1. History of severe , e.g. anaphylaxis or severe systemic response, to immunoglobulin, blood or plasma derived products, or any component of Panzyga.
    2. Immunoglobulin (Ig) A deficiency with antibodies to IgA (\<7 mg/dL).
    3. Hyperviscosity syndromes or known or suspected hypercoagulable conditions as inferred from clinical history, which can increase risks of thrombosis associated with IVIG administration.
    4. History of arterial or venous thrombotic or thromboembolic events (TEEs) within the last year prior to Baseline. History of acquired or inherited thrombophilia any time prior to Baseline.
    5. Need for within three months after receiving study drug.
    6. Renal dysfunction (creatinine >120 µmol/L or 1.36 mg/dL), history of renal dysfunction, or known risk factor for renal dysfunction (chronic renal insufficiency, diabetes mellitus, taking known nephrotoxic medication). For Italy, estimated (eGFR) needs to be calculated with the 2009 Schwartz equation (eGFR = k * height/Serum creatinine (Scr), where k is 0.413) [2]. eGFR must not be below 30.
  4. Severely restricted food intake likely to require parenteral nutrition, and \<5th percentile -for-age (BMI Percentile Calculator for Child and Teen based on Centers for Disease Control and Prevention growth charts for children and teens ages 2 through 19 years)
  5. Body mass index ≥ 40 kg/m2
  6. Presence of symptoms consistent with autism or schizophrenia, bipolar disorder, or other psychotic disorder (unless psychotic symptoms have onset coincident with PANS).
  7. Presence of serious or unstable medical illness, psychiatric (e.g. high suicide risk) or behavioral symptoms that would make participation unsafe or study procedures too difficult to tolerate.
  8. Treatment with systemic within eight weeks before randomization.
  9. Treatment with NSAIDs within five days before randomization.
  10. Treatment with melatonin within one week before randomization
  11. History of rheumatic fever, including SC (neurological manifestation).
  12. Past treatment of neuropsychiatric symptoms with immunomodulatory therapy (such as IVIG, rituximab or mycophenolate mofetil) or plasmapheresis.
  13. Initiation of cognitive behavioral therapy (CBT) within eight weeks before randomization.
  14. Start of treatment or change in dosing with selective serotonin reuptake inhibitors [SSRIs] within eight weeks before randomization.
  15. Treatment with alpha-2 agonists or antipsychotics within eight weeks before randomization.
  16. Start of treatment or change in dosing with stimulants (Methylphenidate, Amphetamine and similar products) for Attention-Deficit Hyperactivity Disorder (ADHD) within four weeks prior to randomization.
  17. Active use of tetrahydrocannabinol (THC) containing agents within four weeks prior to enrollment or during the trial. Use of cannabidiol- (CBD) / cannabimovone- (CBM) containing agents without THC is allowed if started more than eight weeks before enrollment in a stable dose/frequency.
  18. Use of antibiotics or antiviral drugs at therapeutic dose within one week before randomization. Use of antibiotics at a prophylactic dose is allowed if started at least four weeks before randomization (Section 4.2).
  19. Severe liver disease ( [ALT] three times above normal value).
  20. Known , or infection as per patient medical history.
  21. Cardiac insufficiency ( [NYHA] classification III-IV), cardiomyopathy, significant cardiac dysrhythmia requiring treatment.
  22. Medical conditions with symptoms and effects that could alter protein catabolism and/or IgG utilization (e.g. protein-losing enteropathies, nephrotic syndrome).
  23. Pregnant and/or lactating women.
  24. Female patients of unwilling to use a protocol-required method of (as per protocol Section 7.3.9 b) from Screening throughout the study treatment period and for four weeks following the last dose of study drug. A woman of childbearing potential is defined as a fertile woman or adolescent, from the beginning of menstruation, unless permanently sterile.
  25. Participation in another interventional clinical trial that is either blinded or involves an investigational (not approved) product within three months before Baseline or during the course of the clinical study. Participation in observational clinical trials or open-label trials involving an approved product may be permitted after consultation with the medical monitor.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Panzyga

    Panzyga 10% IVIG

    Biological: Panzyga

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • BiologicalPanzyga

    Panzyga 10% IVIG

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Percentage Change in CY-BOCS Score From Baseline to Week 9

    The primary endpoint of this study was the percentage change of neuropsychiatric symptomatology and behavior in PANS patients determined by clinician-rated Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) score. The CY-BOCS scale score is a clinician-rated, semi-structured interview for rating the presence or absence, as well as the severity of obsessive-compulsive symptoms. The CY-BOCS yields a total obsession score, a total compulsion score and combined total score (minimum total CY-BOCS score=0, maximum total CY-BOCS score=40). The mean percentage change in the total CY-BOCS score from Baseline to Week 9 was calculated and compared between Panzyga and Placebo treatment to demonstrate superiority. A value of 0 means there was no change from baseline to week 9. Negative values indicate a worse outcome. Positive values mean a better outcome.

    Time frame: 9 Weeks

Secondary outcomes

  1. Percentage Change in Total CY-BOCS Score From Week 9 to Week 18 Within the (Panzyga - Placebo) Treatment Sequence Group

    The CY-BOCS scores at the end of the follow up period were compared with the Week 9 scores to examine the durability of any clinical benefit following Panzyga treatment in the first 9-week treatment period and whether there was any worsening after crossing over to placebo treatment. The CY-BOCS scale score is a clinician-rated, semi-structured interview for rating the presence or absence, as well as the severity of obsessive-compulsive symptoms. The CY-BOCS yields a total obsession score, a total compulsion score and combined total score (minimum total CY-BOCS score=0, maximum total CY-BOCS score=40). The mean percentage change of the total CY-BOCS score at Week 18 to the Week 9 score was calculated within the (Panzyga - Placebo) treatment sequence group. A value of 0 means there was no change from Week 9 to Week 18. Negative values indicate a worse outcome. Positive values mean a better outcome.

    Time frame: 9 Weeks (Week 9 to Week 18)

  2. Clinical Global Impression - Improvement (CGI-I) Score at Week 9

    The CGI-I rating scale was used to assess behavioral changes in PANS patients. The Clinical Global Impression - Improvement scale (CGI-I) is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention and is rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. The mean CGI-I scores at Week 9 were compared between Panzyga and placebo treatment.

    Time frame: 9 Weeks

Other outcomes

  1. Patients With PANS Improvement From Baseline to Week 9

    The percentage of patients who showed PANS improvement was measured by Clinical Global Impression - Improvement (CGI-I) rating. "The Clinical Global Impression - Improvement is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a Baseline state at the beginning of the intervention and is rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse." PANS improvement was defined as a CGI-I rating of 1 (Very much Improved), 2 (Much improved), or 3 (Minimally Improved). The percentages of improved patients at Week 9 were compared to baseline between Panzyga and placebo treatment.

    Time frame: 9 Weeks

07

Results

Posted Jan 7, 2026

Participant flow

First Intervention (Week 1-9)
Participant flow — First Intervention (Week 1-9)
MilestonePlacebo - PanzygaPanzyga - Placebo
Started3734
Completed3628
Not completed16
Second Intervention (Week 10-18)
Participant flow — Second Intervention (Week 10-18)
MilestonePlacebo - PanzygaPanzyga - Placebo
Started3628
Completed3228
Not completed40

Outcome measures

SecondaryPercentage Change in Total CY-BOCS Score From Week 9 to Week 18 Within the (Panzyga - Placebo) Treatment Sequence Group

The CY-BOCS scores at the end of the follow up period were compared with the Week 9 scores to examine the durability of any clinical benefit following Panzyga treatment in the first 9-week treatment period and whether there was any worsening after crossing over to placebo treatment. The CY-BOCS scale score is a clinician-rated, semi-structured interview for rating the presence or absence, as well as the severity of obsessive-compulsive symptoms. The CY-BOCS yields a total obsession score, a total compulsion score and combined total score (minimum total CY-BOCS score=0, maximum total CY-BOCS score=40). The mean percentage change of the total CY-BOCS score at Week 18 to the Week 9 score was calculated within the (Panzyga - Placebo) treatment sequence group. A value of 0 means there was no change from Week 9 to Week 18. Negative values indicate a worse outcome. Positive values mean a better outcome.

Time frame:
9 Weeks (Week 9 to Week 18)
Reported as:
Mean · Percentage Change at Week 18 to Week 9
Percentage Change in Total CY-BOCS Score From Week 9 to Week 18 Within the (Panzyga - Placebo) Treatment Sequence Group
Percentage Change at Week 18 to Week 9Panzyga - Placebo
Percentage Change in Total CY-BOCS Score From Week 9 to Week 18 Within the (Panzyga - Placebo) Treatment Sequence Group29.4 ± 42.84
SecondaryClinical Global Impression - Improvement (CGI-I) Score at Week 9

The CGI-I rating scale was used to assess behavioral changes in PANS patients. The Clinical Global Impression - Improvement scale (CGI-I) is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention and is rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. The mean CGI-I scores at Week 9 were compared between Panzyga and placebo treatment.

Time frame:
9 Weeks
Reported as:
Mean · score on a scale
Clinical Global Impression - Improvement (CGI-I) Score at Week 9
score on a scalePlacebo - PanzygaPanzyga - Placebo
Clinical Global Impression - Improvement (CGI-I) Score at Week 93.3 ± 1.192.6 ± 1.32
Statistical analysis
  • Placebo - Panzyga vs Panzyga - Placebo · Mixed Models Analysis · p = 0.00855 · Least squares mean difference: 1.1 · 5% CI 0.2 to 2.0
PrimaryPercentage Change in CY-BOCS Score From Baseline to Week 9

The primary endpoint of this study was the percentage change of neuropsychiatric symptomatology and behavior in PANS patients determined by clinician-rated Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) score. The CY-BOCS scale score is a clinician-rated, semi-structured interview for rating the presence or absence, as well as the severity of obsessive-compulsive symptoms. The CY-BOCS yields a total obsession score, a total compulsion score and combined total score (minimum total CY-BOCS score=0, maximum total CY-BOCS score=40). The mean percentage change in the total CY-BOCS score from Baseline to Week 9 was calculated and compared between Panzyga and Placebo treatment to demonstrate superiority. A value of 0 means there was no change from baseline to week 9. Negative values indicate a worse outcome. Positive values mean a better outcome.

Time frame:
9 Weeks
Reported as:
Mean · Percentage Change at Week 9 to Baseline
Percentage Change in CY-BOCS Score From Baseline to Week 9
Percentage Change at Week 9 to BaselinePlacebo - PanzygaPanzyga - Placebo
Percentage Change in CY-BOCS Score From Baseline to Week 912.1 ± 68.3931.1 ± 40.68
Statistical analysis
  • Placebo - Panzyga vs Panzyga - Placebo · t-test, 1 sided · p = 0.0718 · Mean difference (net): -19.0
Other pre-specifiedPatients With PANS Improvement From Baseline to Week 9

The percentage of patients who showed PANS improvement was measured by Clinical Global Impression - Improvement (CGI-I) rating. "The Clinical Global Impression - Improvement is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a Baseline state at the beginning of the intervention and is rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse." PANS improvement was defined as a CGI-I rating of 1 (Very much Improved), 2 (Much improved), or 3 (Minimally Improved). The percentages of improved patients at Week 9 were compared to baseline between Panzyga and placebo treatment.

Time frame:
9 Weeks
Reported as:
Count of participants · Participants
Patients With PANS Improvement From Baseline to Week 9
ParticipantsPlacebo - PanzygaPanzyga - Placebo
PANS Improvement YES1924
PANS Improvement NO175
Statistical analysis
  • Placebo - Panzyga vs Panzyga - Placebo · Chi-squared · p = 0.0111

Adverse events

Collected over 18 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panzyga0/70 (0%)5/70 (7.1%)64/70 (91.4%)
Placebo0/37 (0%)1/37 (2.7%)26/37 (70.3%)
Placebo After Panzyga0/27 (0%)0/27 (0%)19/27 (70.4%)
Most frequent serious events
Most frequent serious events
EventPanzygaPlaceboPlacebo After Panzyga
Respiratory Tract InfectionInfections and infestations0/701/370/27
NauseaGastrointestinal disorders1/700/370/27
VomitingGastrointestinal disorders1/700/370/27
HypertransaminasaemiaHepatobiliary disorders1/700/370/27
HeadacheNervous system disorders1/700/370/27
Obsessive-compulsive DisorderPsychiatric disorders1/700/370/27
HaematuriaRenal and urinary disorders1/700/370/27
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPanzygaPlaceboPlacebo After Panzyga
HeadacheNervous system disorders57/7011/373/27
NauseaGastrointestinal disorders34/708/372/27
VomitingGastrointestinal disorders32/702/372/27
PyrexiaGeneral disorders30/708/373/27
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders4/707/371/27
Upper Abdominal PainGastrointestinal disorders12/703/372/27
FatigueGeneral disorders8/700/370/27
Coombs direct test positiveInvestigations7/700/371/27
Haemoglobin DecreasedInvestigations7/701/370/27
DiarrhoeaGastrointestinal disorders6/702/371/27

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo - PanzygaPanzyga - PlaceboTotal
<=18 years373471
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)Placebo - PanzygaPanzyga - PlaceboTotal
Mean9.8 ± 2.959.3 ± 2.529.5 ± 2.74
Sex: Female, Male
Sex: Female, Male(Participants)Placebo - PanzygaPanzyga - PlaceboTotal
Female191130
Male182341
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo - PanzygaPanzyga - PlaceboTotal
Hispanic or Latino538
Not Hispanic or Latino323062
Unknown or Not Reported011
Body Mass Index
Body Mass Index(kg/m^2)Placebo - PanzygaPanzyga - PlaceboTotal
Mean18.99 ± 3.98019.18 ± 4.75519.08 ± 4.337
08

Study locations

12 sites
  • Octapharma Research Site
    Tucson, Arizona 85712, United States
  • Octapharma Research Site
    Little Rock, Arkansas 72202, United States
  • Octapharma Research Site
    Los Angeles, California 90024, United States
  • Octapharma Research Site
    Palo Alto, California 94305, United States
  • Octapharma Research Site
    Centennial, Colorado 80112, United States
  • Octapharma Research Site
    Boston, Massachusetts 02114, United States
  • Octapharma Research Site
    Lebanon, New Hampshire 03756, United States
  • Octapharma Research Site
    Genova, 16147, Italy
  • Octapharma Research Site
    Roma, 00161, Italy
  • Octapharma Research Site
    Roma, 00186, Italy
  • Octapharma Research Site
    Gothenburg, 41685, Sweden
  • Octapharma Research Site
    Stockholm, 17164, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Aug 2024, 37 months.

Results were first posted in Jan 2026, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2020
First posted
Aug 11, 2020
StartActual
Jun 30, 2021
Primary completionActual
Aug 27, 2024
CompletionActual
Oct 30, 2024
Results first posted
Jan 7, 2026
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04508530
Lead sponsor
Octapharma
Responsible party
Sponsor
First posted
Aug 11, 2020
Start date
Jun 30, 2021
Primary completion
Aug 27, 2024
Completion
Oct 30, 2024
Results posted
Jan 7, 2026
Last update
Jan 7, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panzyga

Start the discussion